AdaptiveMobile Detects Sophisticated Attacks on Signalling Networks across Five Continents
26.2.2018 09:00:00 EET | Business Wire | Press release
MOBILE WORLD CONGRESS – AdaptiveMobile Security, the world leader in mobile network security, today announced it has detected increasingly sophisticated attacks via the next generation of signalling protocols being used for 4G. In new research released at Mobile World Congress 2018, AdaptiveMobile presented the industry’s first ever overview of real-life attacks launched over the Diameter protocol.
“This research is the final piece of intel that will drive mobile operators to put defences in place to protect their networks against attacks over Diameter. Diameter vulnerabilities were theoretical up until now; however, this new research clearly demonstrates that they are actually being exploited in the real world, meaning the risk is real and must be addressed,” said Cathal Mc Daid, Chief Intelligence Officer of AdaptiveMobile Security.
To acquire these insights, the Company performed analysis of international Diameter traffic from ten operators’ networks worldwide and found suspicious activity within them. The research conducted analysed Diameter traffic travelling to and from more than 80 countries across five continents and detected a range of malicious activity, from simple to complex, over Diameter networks, affecting both mobile subscribers and mobile networks.
“Most importantly, carriers need to understand what is being detected and cannot rely on simple categorisation or rules to decipher what is malicious activity and what is not.” Mc Daid continued: “The threat is now proven, but without an added layer of intelligence, malicious traffic will be hidden in amongst the noise. This is critical, as Diameter use widens and SS7 security improves we expect rogue actors to exploit Diameter more and more.”
AdaptiveMobile has been working with operator networks around the globe to analyse their SS7 network data since launching its Signalling Protection in 2015. The Diameter protocol is the next-generation in signalling networks and as service providers roll out IP-based LTE networks – which present an evolved threat landscape – there is a growing demand for broader signalling protection on both SS7 and Diameter networks.
To learn more about AdaptiveMobile Security’s Signalling Protection product and industry-leading Threat Intelligence Unit, visit AdaptiveMobile at MWC in Hall 2, 2D100MR.
About
AdaptiveMobile Security
AdaptiveMobile Security
is the world leader in mobile network security, protecting over 1.7
billion subscribers worldwide, and the only mobile security company
offering products designed to protect all services on both fixed and
mobile networks through in-network and cloud solutions. With deep
expertise and a unique focus on network-to-handset security,
AdaptiveMobile’s award-winning security solutions provide its customers
with advanced threat detection and actionable intelligence, combined
with the most comprehensive security products on the market today.
AdaptiveMobile was founded in 2004 and boasts some of the world’s largest mobile operators as customers and the leading security and telecom equipment vendors as partners. The Company is headquartered in Dublin with offices in North America, Europe, South Africa, the Middle East and Asia Pacific.
https://www.adaptivemobile.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180225005220/en/
Contact information
AxiCom for AdaptiveMobile Security
James Hayward, +44 7809 495 760
james.hayward@axicom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
